Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
Lancet Gastroenterol Hepatol
    March 2026
  1. D'HAENS GR, Oldenburg L, Hulshoff MS
    Vedolizumab treatment outcomes in early versus late Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2026;11:184-185.
    >> Share

  2. CHEN R, Croitoru K, Lee SH
    Vedolizumab treatment outcomes in early versus late Crohn's disease.
    Lancet Gastroenterol Hepatol. 2026;11:183-184.
    >> Share

  3. NOOR NM, Hart AL, Lee JC, Parkes M, et al
    Vedolizumab treatment outcomes in early versus late Crohn's disease.
    Lancet Gastroenterol Hepatol. 2026;11:182-183.
    >> Share

    February 2026
  4. OLDENBURG L, Haanappel AEG, Ali M, Bosman C, et al
    Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial.
    Lancet Gastroenterol Hepatol. 2026 Feb 19:S2468-1253(25)00374.
    >> Share

  5. HONAP S, Jairath V, Magro F, Danese S, et al
    Clinical remission in ulcerative colitis: restoring precision in trial terminology.
    Lancet Gastroenterol Hepatol. 2026;11:96-97.
    >> Share

    January 2026
  6. ARMET AM, Wine E
    Cyclic exclusive enteral nutrition: a novel approach to maintaining remission in paediatric Crohn's disease.
    Lancet Gastroenterol Hepatol. 2026 Jan 19:S2468-1253(25)00325.
    >> Share

  7. PIGNEUR B, Martinez-Vinson C, Bourmaud A, Dabadie A, et al
    Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2026 Jan 19:S2468-1253(25)00262.
    >> Share

  8. LONG M, Allegretti JR, Danese S, Germinaro M, et al
    Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial.
    Lancet Gastroenterol Hepatol. 2026 Jan 13:S2468-1253(25)00322.
    >> Share

  9. CONLEY S, Kamp KJ, Kane SV
    Menopause and inflammatory bowel disease: more questions than answers.
    Lancet Gastroenterol Hepatol. 2026 Jan 13:S2468-1253(25)00368.
    >> Share

  10. COHEN NA, Bettenworth D, Sror N, Khedraki R, et al
    Definitions, diagnosis, management, and outcomes of upper gastrointestinal Crohn's disease: an international, expert RAND/UCLA appropriateness study.
    Lancet Gastroenterol Hepatol. 2026 Jan 8:S2468-1253(25)00347.
    >> Share

  11. TODESCATTO AD, Kotze PG
    Appendicectomy: a disease-modifying treatment for ulcerative colitis?
    Lancet Gastroenterol Hepatol. 2026 Jan 6:S2468-1253(25)00303.
    >> Share

  12. VISSER E, Reijntjes MA, Heuthorst L, Stellingwerf ME, et al
    Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study.
    Lancet Gastroenterol Hepatol. 2026 Jan 6:S2468-1253(25)00291.
    >> Share

    November 2025
  13. SHEBAB M, Al-Hindawi A, Goodwin SW, Yuan Y, et al
    Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2025 Nov 25:S2468-1253(25)00346.
    >> Share

  14. VUIJK SA, Boute EH, de Ridder L
    Expanding the therapeutic arsenal for paediatric ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025 Nov 18:S2468-1253(25)00234.
    >> Share

  15. KAPLAN JL, Bousvaros A, Turner D, Dubinsky M, et al
    Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial.
    Lancet Gastroenterol Hepatol. 2025 Nov 18:S2468-1253(25)00196.
    >> Share

  16. DE BOER NK, Gearry RB, Bernstein CN, Banerjee R, et al
    The essential medicines list for inflammatory bowel disease: time to raise the standards of global care.
    Lancet Gastroenterol Hepatol. 2025 Nov 17:S2468-1253(25)00299.
    >> Share

  17. JAIRATH V, Danese S, D'Haens GR, Feagan BG, et al
    Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial.
    Lancet Gastroenterol Hepatol. 2025 Nov 13:S2468-1253(25)00296.
    >> Share

  18. ATREYA R, Neurath MF
    Dual targeting of TNF and IL-23 by a bispecific antibody in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025 Nov 13:S2468-1253(25)00330.
    >> Share

  19. LI YIM AYF, Levin E, de Jonge WJ, Henneman P, et al
    Peripheral blood DNA methylation signatures to predict treatment response in Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:973-974.
    >> Share

  20. LI H, Zeng J, Zhang L, Guo Q, et al
    Peripheral blood DNA methylation signatures to predict treatment response in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:972-973.
    >> Share

    October 2025
  21. EGGERMONT E, Gecse K, Krugliak Cleveland N, Petersen F, et al
    Ulcerative colitis: moving beyond the mucosal dogma.
    Lancet Gastroenterol Hepatol. 2025 Oct 28:S2468-1253(25)00263.
    >> Share

  22. HOIVIK ML
    Optimising treatment in Crohn's disease: is the main issue early versus late or biologic naive versus biologic experienced?
    Lancet Gastroenterol Hepatol. 2025 Oct 27:S2468-1253(25)00258.
    >> Share

  23. D'HAENS GR, Lowenberg M, Baert F, Bossuyt P, et al
    Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study.
    Lancet Gastroenterol Hepatol. 2025 Oct 27:S2468-1253(25)00233.
    >> Share

    September 2025
  24. WU K, Zheng C, Cao Q, Ding Y, et al
    Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
    Lancet Gastroenterol Hepatol. 2025 Sep 30:S2468-1253(25)00198.
    >> Share

  25. VISSER E, Buskens CJ
    Appendicectomy for ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:789-790.
    >> Share

  26. SCARPA M, Castagliuolo I, Kotsafti A, Angriman I, et al
    Appendicectomy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:788.
    >> Share

  27. BRONZE S, Agrawal M, Rodriguez-Lago I, Colombel JF, et al
    Appendicectomy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:788-789.
    >> Share

    July 2025
  28. DANESE S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, et al
    Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.
    Lancet Gastroenterol Hepatol. 2025 Jul 21:S2468-1253(25)00129.
    >> Share

  29. YOGAKANTHI S, Raine T
    Progress in validation of treatment-response biomarkers in Crohn's disease?
    Lancet Gastroenterol Hepatol. 2025 Jul 1:S2468-1253(25)00138.
    >> Share

  30. JOUSTRA VW, Li Yim AYF, Henneman P, Hageman I, et al
    Development and validation of peripheral blood DNA methylation signatures to predict response to biological therapy in adults with Crohn's disease (EPIC-CD): an epigenome-wide association study.
    Lancet Gastroenterol Hepatol. 2025 Jul 1:S2468-1253(25)00102.
    >> Share

    June 2025
  31. BOUHNIK Y, Mary JY
    A new endoscopic paradigm: evaluating the EASE-CD score for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025 Jun 9:S2468-1253(25)00127.
    >> Share

  32. MA C, Khanna R, Maguire BR, Zou G, et al
    Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trials.
    Lancet Gastroenterol Hepatol. 2025 Jun 9:S2468-1253(25)00093.
    >> Share

  33. PANACCIONE R, Vermeire S, Danese S, Higgins PDR, et al
    Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study.
    Lancet Gastroenterol Hepatol. 2025;10:507-519.
    >> Share

  34. NOOR NM, Parkes M, Raine T
    U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:492-493.
    >> Share

  35. NEURATH MF, Artis D, Becker C
    The intestinal barrier: a pivotal role in health, inflammation, and cancer.
    Lancet Gastroenterol Hepatol. 2025;10:573-592.
    >> Share

    May 2025
  36. FEAGAN BG, Sands BE, Siegel CA, Dubinsky MC, et al
    Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.
    Lancet Gastroenterol Hepatol. 2025 May 30:S2468-1253(25)00071.
    >> Share

  37. LINDSAY J
    Tulisokibart shows promise for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025 May 30:S2468-1253(25)00103.
    >> Share

    April 2025
  38. HANNA LN, Munster LJ, Joshi S, Wendelien van der Bilt JD, et al
    Isolated perianal Crohn's disease: a systematic review and expert consensus proposing novel diagnostic criteria and management advice.
    Lancet Gastroenterol Hepatol. 2025 Apr 29:S2468-1253(25)00007.
    >> Share

  39. UKASHI O, Ben-Horin S
    Appendicectomy: a novel treatment for ulcerative colitis?
    Lancet Gastroenterol Hepatol. 2025 Apr 11:S2468-1253(25)00065.
    >> Share


  40. Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial.
    Lancet Gastroenterol Hepatol. 2025 Apr 11:S2468-1253(25)00026.
    >> Share

  41. HONAP S, Agrinier N, Torres J, Croitoru K, et al
    Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design.
    Lancet Gastroenterol Hepatol. 2025 Apr 2:S2468-1253(24)00439.
    >> Share

    March 2025
  42. SHENOY S, Jena A, Levinson C, Sharma V, et al
    Inflammatory bowel disease in south Asia: a scoping review.
    Lancet Gastroenterol Hepatol. 2025;10:259-274.
    >> Share

  43. D'HAENS G
    Vedolizumab for prevention of recurrence of Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:194-195.
    >> Share

  44. HAMMOUDI N, Allez M
    Vedolizumab for prevention of recurrence of Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:193.
    >> Share

  45. NGUYEN A, Li Wai Suen CFD, Srinivasan A, Segal J, et al
    Vedolizumab for prevention of recurrence of Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:193-194.
    >> Share

    February 2025
  46. TEMIDO MJ, Honap S, Jairath V, Vermeire S, et al
    Overcoming the challenges of overtreating and undertreating inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2025 Feb 4:S2468-1253(24)00355.
    >> Share

  47. NOOR NM, Estevinho MM, Solitano V, Yuan Y, et al
    Applying the estimand framework to inflammatory bowel disease clinical trials.
    Lancet Gastroenterol Hepatol. 2025 Feb 3:S2468-1253(25)00004.
    >> Share

    January 2025
  48. SANDS BE, Panaccione R, D'Haens G, Schreiber S, et al
    Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial.
    Lancet Gastroenterol Hepatol. 2025 Jan 7:S2468-1253(24)00386.
    >> Share

  49. ATREYA R, Neurath MF
    No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025 Jan 7:S2468-1253(24)00397.
    >> Share

  50. ATIA O, Shavit-Brunschwig Z, Lev-Tzion R, Stein R, et al
    Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study.
    Lancet Gastroenterol Hepatol. 2025 Jan 6:S2468-1253(24)00319.
    >> Share

  51. LI WAI SUEN CFD, Choy MC, Con D, De Cruz P, et al
    Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:19.
    >> Share

  52. HOFFERT Y, Ferrante M, Verstockt B, Dreesen E, et al
    Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:18-19.
    >> Share

  53. COMAN D, Battat R
    Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:17-18.
    >> Share

  54. VAN DER DOES DE WILLEBOIS EML, Bemelman WA, Buskens CJ
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:16-17.
    >> Share

  55. COFFEY JC, Li Y, Walsh D, Connelly TM, et al
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:15.
    >> Share

  56. KELM M, Flemming S
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:15-16.
    >> Share

  57. DUAN M, Li Y
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:14-15.
    >> Share

  58. YADAV A
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:14.
    >> Share

    December 2024
  59. AINSWORTH MA
    Does filgotinib work for Crohn's disease?
    Lancet Gastroenterol Hepatol. 2024 Dec 2:S2468-1253(24)00304.
    >> Share

  60. VERMEIRE S, Schreiber S, Rubin DT, D'Haens G, et al
    Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Dec 2:S2468-1253(24)00272.
    >> Share

    November 2024
  61. D'HAENS G, Taxonera C, Lopez-Sanroman A, Nos P, et al
    Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Nov 18:S2468-1253(24)00317.
    >> Share

  62. MULLIGAN RJ, Lamb CA
    Vedolizumab prophylaxis against postoperative Crohn's disease recurrence.
    Lancet Gastroenterol Hepatol. 2024 Nov 18:S2468-1253(24)00352.
    >> Share

  63. ANDERSEN V, Pingel J, Sofelt HL, Hikmat Z, et al
    Sex and gender in inflammatory bowel disease outcomes and research.
    Lancet Gastroenterol Hepatol. 2024;9:1041-1051.
    >> Share

  64. GOMOLLON F
    Do placebos harm patients in IBD trials?
    Lancet Gastroenterol Hepatol. 2024;9:970-972.
    >> Share

    October 2024
  65. LU C, Rosentreter R, Parker CE, Remillard J, et al
    International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement.
    Lancet Gastroenterol Hepatol. 2024 Oct 21:S2468-1253(24)00265.
    >> Share

    September 2024
  66. GROS B, Blackwell J, Segal J, Black CJ, et al
    Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2024 Sep 19:S2468-1253(24)00233.
    >> Share

  67. DIN S, Segal J, Blackwell J, Gros B, et al
    Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2024 Sep 19:S2468-1253(24)00264.
    >> Share

  68. KEDIA S, Ahuja V
    Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better.
    Lancet Gastroenterol Hepatol. 2024 Sep 2:S2468-1253(24)00229.
    >> Share

  69. CHOY MC, Li Wai Suen CFD, Con D, Boyd K, et al
    Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Sep 2:S2468-1253(24)00200.
    >> Share

    July 2024
  70. NOOR NM, Sebastian S, Parkes M, Raine T, et al
    The need for affordable, pragmatic, investigator-led clinical trials of treatment strategies in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2024 Jul 30:S2468-1253(24)00225.
    >> Share

  71. VAN DER DOES DE WILLEBOIS EML, Bellato V, Duijvestein M, van der Bilt JDW, et al
    Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Jul 15:S2468-1253(24)00097.
    >> Share

  72. CLICK B, Holubar SD
    Targeting the mesentery with surgery in ileocolic Crohn's disease: where do we stand?
    Lancet Gastroenterol Hepatol. 2024 Jul 15:S2468-1253(24)00186.
    >> Share

  73. CHEN R, Zhang S
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:592.
    >> Share

  74. NOOR NM, Lee JC, Bond S, Parkes M, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial - Authors' reply.
    Lancet Gastroenterol Hepatol. 2024;9:592-594.
    >> Share

  75. BORKAR V, Lunagariya Y, Chopra S, Sasikumar D, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:591.
    >> Share

  76. SATSANGI J, Nowak J, Kalla R, Colombel JF, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:591-592.
    >> Share

  77. BOURGONJE AR, Visschedijk MC, Festen EAM, Weersma RK, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:590-591.
    >> Share

    June 2024
  78. GUPTA A, Guisado D, Ricart E, Colombel JF, et al
    Haematopoietic stem-cell transplantation in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2024;9:499-500.
    >> Share

    May 2024
  79. IACUCCI M, Santacroce G, Zammarchi I, Maeda Y, et al
    Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2024 May 14:S2468-1253(24)00053.
    >> Share

  80. BETHLEHEM L, Estevinho MM, Grinspan A, Magro F, et al
    Microbiota therapeutics for inflammatory bowel disease: the way forward.
    Lancet Gastroenterol Hepatol. 2024;9:476-486.
    >> Share

  81. FUMERY M, Buisson A
    Has the time come for a systematic top-down approach in Crohn's disease?
    Lancet Gastroenterol Hepatol. 2024;9:394-395.
    >> Share

    April 2024
  82. PARKES GC, Hedin CRH
    PANTS extension study: how best to use anti-TNF drugs in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2024 Apr 16:S2468-1253(24)00088.
    >> Share

  83. CHANCHLANI N, Lin S, Bewshea C, Hamilton B, et al
    Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
    Lancet Gastroenterol Hepatol. 2024 Apr 16:S2468-1253(24)00044.
    >> Share

    March 2024
  84. BALDERRAMO D, Quaresma AB, Olivera PA, Savio MC, et al
    Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America.
    Lancet Gastroenterol Hepatol. 2024;9:263-272.
    >> Share

  85. RIVIERE P, Li Wai Suen C, Chaparro M, De Cruz P, et al
    Acute severe ulcerative colitis management: unanswered questions and latest insights.
    Lancet Gastroenterol Hepatol. 2024;9:251-262.
    >> Share

    February 2024
  86. CHAPMAN TP, Ahmad T, Satsangi J
    Use of immunomodulators in combination with infliximab in Crohn's disease: time for a reappraisal?
    Lancet Gastroenterol Hepatol. 2024 Feb 22:S2468-1253(23)00406.
    >> Share

  87. NOOR NM, Lee JC, Bond S, Dowling F, et al
    A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Feb 21:S2468-1253(24)00034.
    >> Share

  88. CICCOCIOPPO R, Gaspar L
    Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere.
    Lancet Gastroenterol Hepatol. 2024 Feb 7:S2468-1253(24)00004.
    >> Share

  89. LINDSAY JO, Hind D, Swaby L, Berntsson H, et al
    Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, ra
    Lancet Gastroenterol Hepatol. 2024 Feb 7:S2468-1253(23)00460.
    >> Share

    January 2024
  90. SEBASTIAN S, Siegmund B, Teferra F, McGovern DPB, et al
    Promoting equity in inflammatory bowel disease: a global approach to care.
    Lancet Gastroenterol Hepatol. 2024 Jan 11:S2468-1253(23)00368.
    >> Share

    December 2023
  91. FUMERY M, Buisson A
    Guselkumab in Crohn's disease: the IL-23 race continues.
    Lancet Gastroenterol Hepatol. 2023 Dec 14:S2468-1253(23)00356.
    >> Share

  92. DANESE S, Panaccione R, Feagan BG, Afzali A, et al
    Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
    Lancet Gastroenterol Hepatol. 2023 Dec 14:S2468-1253(23)00318.
    >> Share

    October 2023
  93. DIBLEY L, Duffy M
    Inflammatory bowel disease health care for LGTBQIA+ patients.
    Lancet Gastroenterol Hepatol. 2023 Oct 20:S2468-1253(23)00352.
    >> Share

  94. PATHIYIL MM, Jena A, Venkataramana Raju AK, Omprakash TA, et al
    Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review.
    Lancet Gastroenterol Hepatol. 2023 Oct 10:S2468-1253(23)00193.
    >> Share

  95. QUAN J, Markovinovic A, Hracs L, Ma C, et al
    Bivalent mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Oct 6:S2468-1253(23)00310.
    >> Share

    September 2023
  96. VERMEIRE S, Danese S, Zhou W, Ilo D, et al
    Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-bl
    Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00208.
    >> Share

  97. ATREYA R, Neurath MF
    Further efficacy and safety data for maintenance upadacitinib in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00271.
    >> Share

    August 2023
  98. SENIOR K
    Surgery in Crohn's disease: patients need MDT-led holistic care.
    Lancet Gastroenterol Hepatol. 2023 Aug 8:S2468-1253(23)00274.
    >> Share

  99. SHIN A
    Psychological therapies in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Aug 2:S2468-1253(23)00229.
    >> Share

  100. RIGGOTT C, Mikocka-Walus A, Gracie DJ, Ford AC, et al
    Efficacy of psychological therapies in people with inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2023 Aug 2:S2468-1253(23)00186.
    >> Share

    July 2023
  101. PARIGI TL, D'Amico F, Abreu MT, Dignass A, et al
    Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting.
    Lancet Gastroenterol Hepatol. 2023 Jul 6:S2468-1253(23)00154.
    >> Share

    May 2023
  102. JULSGAARD M, Mahadevan U, Vestergaard T, Mols R, et al
    Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2023 May 31:S2468-1253(23)00158.
    >> Share

  103. JAGT JZ, van Rheenen PF, Thoma SMA, Gower J, et al
    The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership.
    Lancet Gastroenterol Hepatol. 2023 May 22:S2468-1253(23)00140.
    >> Share

  104. JENA A, Sharma V, Sebastian S
    Reducing disparities in training in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 May 10:S2468-1253(23)00105.
    >> Share

  105. BRIERLEY R
    18th Congress of the European Crohn's and Colitis Organisation.
    Lancet Gastroenterol Hepatol. 2023;8:404.
    >> Share

  106. LOUIS E
    Treatment de-escalation in Crohn's disease - Author's reply.
    Lancet Gastroenterol Hepatol. 2023;8:401-402.
    >> Share

  107. MCSHANE C, Kevans D
    Treatment de-escalation in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2023;8:401.
    >> Share

  108. THE LANCET GASTROENTEROLOGY HE
    The economic burden of inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023;8:391.
    >> Share

    April 2023
  109. SINGH S, Boland BS, Jess T, Moore AA, et al
    Management of inflammatory bowel diseases in older adults.
    Lancet Gastroenterol Hepatol. 2023;8:368-382.
    >> Share

    March 2023
  110. MASSIRONI S, Vigano C, Palermo A, Pirola L, et al
    Inflammation and malnutrition in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Mar 15:S2468-1253(23)00011.
    >> Share

  111. BANERJEE R, Raghunathan N, Pal P
    Managing inflammatory bowel disease: what to do when the best is unaffordable?
    Lancet Gastroenterol Hepatol. 2023 Mar 2:S2468-1253(23)00062.
    >> Share

  112. BURISCH J, Zhao M, Odes S, De Cruz P, et al
    The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission.
    Lancet Gastroenterol Hepatol. 2023 Mar 2:S2468-1253(23)00003.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016